Xarelto Lawsuit Filings Keep Coming

Published on October 1, 2015 by Sandy Liebhard

Text-Size:A A A+

 

Xarelto lawsuits continue to pile up in courts around the country. Most recently, 12 plaintiffs filed suit in Louisiana federal court accusing Johnson & Johnson and Bayer Corp. of downplaying the risk of internal hemorrhaging associated with the new-generation blood thinner.

According to Law360.com, two of the plaintiffs represent the estates of people who allegedly died due to Xarelto bleeding. All claim that the defendants’ misleading marketing campaigned induced their physicians to prescribe Xarelto instead of safer alternatives.

“The use of Xarelto without appropriate blood monitoring, dose adjustment and twice a day dosing can cause major, life-threatening bleeding events,” the plaintiffs said. “Importantly, Xarelto’s significant risk of severe, and sometimes fatal, internal bleeding has no antidote to reverse its effects.”

Xarelto among Fastest Growing Product Liability Litigations

The new filings helped push the number of Xarelto lawsuits now pending in the U.S. District Court, Eastern District of Louisiana above 2,500 cases. According to a report from Reuters, the consolidated litigation currently underway in that jurisdiction is now one of the fastest-growing products liability dockets in the country.

Earlier this month, the Court issued a new Case Management Order indicating that it would convene four bellwether trials starting in February 2017. The first two will take place in the Eastern District of Louisiana, while one each will be venued in yet-to-be-determined districts in Texas and Mississippi. The process of selecting cases for those trials will begin next year.

Xarelto is a new blood thinning medication that was intended to replace warfarin, an anticoagulant that has been on the market for decades. However, there currently exists no approved antidote to reverse Xarelto bleeding side effects. Warfarin can also cause internal bleeding, but such complications can be stopped via the administration of vitamin K.

In the U.S., Xarelto is approved for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. The drug’s label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.

Attorneys at Bernstein Liebhard LLP represent Xarelto plaintiffs, and they continue to provide free legal reviews to those who may have been harmed by this drug. To learn more, please call (888) 979-1182.

Web Analytics